Bikas Sharma, MD
Family Medicine · Las Vegas, NVNPI 1710199245
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.8% of the total across 165 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 32 manufacturers reported payments, led by AbbVie at 37.1% of the total.
Across 165 payments — averaging $18.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$250
- Almatica Pharma LLC$204
- Novo Nordisk$152
- GSK$133
- Bard Peripheral Vascular, Inc.$110
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,98099%
- Education$201%
- Entertainment$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 71 | $1,118 |
| AstraZeneca | 15 | $250 |
| Almatica Pharma LLC | 10 | $204 |
| Novo Nordisk | 7 | $152 |
| GSK | 6 | $133 |
| Bard Peripheral Vascular, Inc. | 1 | $110 |
| New Horizon Medical Solutions | 1 | $94 |
| Amgen(2 entities) | 4 | $74 |
| Philips North America LLC | 3 | $73 |
| Kyowa Kirin, Inc. | 3 | $63 |
| Nestle Healthcare Nutrition Inc. | 4 | $60 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $55 |
| Bayer | 3 | $54 |
| Idorsia Pharmaceuticals US Inc | 3 | $51 |
| Johnson & Johnson(2 entities) | 4 | $47 |
| Pfizer | 2 | $47 |
| Eisai Inc. | 2 | $43 |
| Kowa Pharmaceuticals America, Inc. | 2 | $41 |
| Merck | 2 | $40 |
| Exact Sciences | 2 | $38 |
| Arbor Pharmaceuticals, Inc. | 2 | $36 |
| Azurity Pharmaceuticals, Inc. | 2 | $35 |
| Astellas Pharma US Inc | 2 | $35 |
| Bausch Health US, LLC | 2 | $30 |
| IBSA Pharma Inc. | 1 | $19 |
| Abbott | 1 | $19 |
| Boehringer Ingelheim | 1 | $18 |
| Biohaven Pharmaceuticals, Inc. | 1 | $18 |
| Optos, Inc. | 1 | $15 |
| Lilly USA, LLC | 1 | $15 |
| Galderma Laboratories, L.p. | 1 | $14 |
| Aimmune Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUTONIX$110
How this compares
$3,016 in reported general payments places this provider in the 85th percentile of 902 family medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 34 | $52,139 |
| FarxigaDapagliflozin Propanediol | 38 | $36,667 |
| EliquisApixaban | 28 | $32,748 |
| JardianceEmpagliflozin | 24 | $27,860 |
| LinzessLinaclotide | 25 | $23,634 |
| MyrbetriqMirabegron | 36 | $21,578 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $18,455 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $14,604 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $11,512 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $6,588 |
| Advair DiskusFluticasone Propion/Salmeterol | 17 | $3,990 |
| Celecoxib | 31 | $3,192 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 55 | $2,307 |
| Novolog FlexpenInsulin Aspart | 16 | $1,977 |
| Atorvastatin Calcium | 242 | $1,271 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $152 | $52,13934 claims |
| AstraZenecaFarxiga | $250 | $36,66738 claims |
| PfizerEliquis | $47 | $32,74828 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $133 | $29,96742 claims |
| Boehringer IngelheimJardiance | $18 | $27,86024 claims |
| AbbVieLinzess, Synthroid | $1,118 | $24,34538 claims |
| Astellas Pharma US IncMyrbetriq | $35 | $21,57836 claims |
| MerckJanumet | $40 | $6,58813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 902 family medicine providers in Nevada.
Other family medicine in Las Vegas
- Naz WahabLas Vegas$563K
- Jerry CadeLas Vegas$180K
- Nilesh GokalLas Vegas$75K
- Warren MagnusLas Vegas$70K
- Kimberly AdamsLas Vegas$51K
- Mandeep GillLas Vegas$24K
- Francis JimenezLas Vegas$20K
- Ryan HuangLas Vegas$18K
- Ma Francesca ChamianLas Vegas$17K
- Leo CapobiancoLas Vegas$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.